Market Minds Advisory
Connected RHM (Remote Healthcare Monitoring) Market

Connected RHM (Remote Healthcare Monitoring) Market: Connected Remote Healthcare Monitoring Market. Trends and Forecast 2026 to 2036

Health systems facing chronic disease caseloads that outpace clinic capacity are shifting routine vital sign tracking onto connected home devices, forcing device makers to prove clinical-grade reliability outside the hospital.

Lead Analyst

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$9.5BMarket Size 2025
2036 FORECAST VALUE$33.0BBase Case , 2026 to 2036
CAGR 2026 TO 203612.0 %Bull 13.3% / Bear 10.7%
INCREMENTAL OPPORTUNITY$22.4BNet 10- year value creation
EXPANSION MULTIPLE3.11x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory.

Remote healthcare monitoring stopped being a pandemic-era stopgap the year reimbursement codes made continuous connected monitoring a permanent line item in chronic disease management budgets rather than a temporary telehealth substitute. Health systems now track vital signs continuously through connected devices, catching deterioration between scheduled appointments.
AI-powered chronic disease monitoring platforms lead current spending, concentrated most heavily among health systems managing large diabetic, cardiac, and hypertensive patient populations where continuous data reduces costly emergency interventions. North America and East Asia account for the bulk of current deployment, reflecting both large existing reimbursement infrastructure and, across expanding aging populations, sustained chronic disease management investment nationwide. Government aging population health programs are reinforcing this demand pattern considerably nationwide.
Established medical device manufacturers historically selling standalone monitoring hardware are racing to add connected platform capability before pure-play digital health startups capture the entire care provider relationship for themselves. Value-based care reimbursement models are compounding this competitive pressure, pushing health systems toward vendors offering validated clinical outcome data that differentiates compliant platforms from less rigorous competing offerings still relying on unvalidated consumer wearable data. Vendors report faster procurement once validation data is embedded into specifications.
Market Definition
The Connected RHM Market covers connected devices and software platforms for continuous remote monitoring of patient vital signs and chronic disease indicators outside clinical settings, measured by device and subscription revenue. It excludes standalone consumer fitness wearables without clinical monitoring certification and general telehealth video consultation platforms.
Base Year Value
$9.5B in 2025 (MMA Primary Research Dataset, September 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
12.0% base case. Bull 13.3%. Bear 10.7%.
Fastest Growth Segment
AI-Powered Chronic Disease Monitoring Platforms: 17.0% CAGR
Fastest Growth Country
India: 15.0% CAGR
Fastest Growth Region
South Asia and Pacific: 14.0% CAGR
Largest Region
North America: 32% of 2025 global value
Market Leaders
Leading participants include Philips, Medtronic, Teladoc Health, Vivify Health, and Biotricity.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Connected RHM (Remote Healthcare Monitoring) Market Forecast Scenarios

connected-rhm-remote-healthcare-monitoring-market-size-forecast-scenario-1788423533581
Connected remote healthcare monitoring demand grew steadily from 2020 through 2025, moving from pandemic-driven emergency telehealth substitution toward permanent chronic disease management infrastructure as reimbursement frameworks matured and clinical outcome data validated continuous monitoring benefits. Growth accelerated meaningfully once payers established sustainable reimbursement codes for remote monitoring services, growing at an estimated 10.5% annual rate historically as health systems validated reduced hospitalization rates.
MMA's base case rests on three compounding mechanisms: expanding value-based care reimbursement models increasingly reward health systems for documented remote monitoring outcomes, aging populations require increasingly continuous chronic disease tracking that periodic clinic visits cannot economically provide, and falling connected device costs make comprehensive monitoring programs commercially viable for smaller regional health systems previously priced out. Together these mechanisms push adoption well beyond large academic medical centers into broader community health system procurement.
The bull case centers on a single catalyst: expanding artificial intelligence-powered predictive analytics that flag patient deterioration before symptoms become clinically apparent, driving sustained platform demand. The bear risk is reimbursement policy reversal, where payers facing rising overall healthcare costs restrict remote monitoring coverage in favor of established in-clinic visit models that payers already have well-established reimbursement frameworks for from decades of prior coverage.

Chronic Care Moves From Clinic to Living Room

Connected remote monitoring succeeded where earlier telehealth attempts stalled largely because continuous vital sign data lets care teams intervene before a chronic condition deteriorates into an emergency room visit, rather than relying on periodic in-clinic snapshots that can miss gradual decline between scheduled appointments. Health systems piloting these platforms report measurable hospitalization reduction within a single enrollment year, convincing skeptical care teams who assumed remote data could not replace in-person assessment.
MARKET CONCENTRATION36% CR5Top five vendors hold this combined revenue share currently
AVERAGE PROGRAM COST$85 per patient monthlyTypical monthly subscription cost per enrolled monitored patient
TOP CONSUMING COUNTRY34% United StatesShare of global connected monitoring platform revenue reported here
HOSPITALIZATION REDUCTION RATE28% lowerEstimated reduction in hospital readmissions for enrolled chronic patients
PATIENT ENROLLMENT RATE22% of eligible patientsShare of eligible chronic disease patients currently enrolled in programs
DEVICE BATTERY LIFE5 to 7 daysTypical operating duration before wearable device requires recharging
Procurement now runs through care management and value-based contracting teams rather than individual physicians ordering monitoring devices independently, reflecting growing awareness that platform choices carry reimbursement documentation and clinical outcome implications extending well beyond any single patient's immediate monitoring needs. This shift toward centralized procurement is consolidating vendor relationships around platforms offering comprehensive outcome reporting, favoring established manufacturers over smaller startups lacking dedicated clinical validation teams.
Predictive analytics capability is emerging as a genuine competitive differentiator between monitoring platform vendors, since care teams increasingly expect algorithms that flag deterioration risk before symptoms become clinically apparent rather than simply displaying raw vital sign trends for manual review. Vendors offering credible predictive analytics report meaningfully higher contract renewal rates than those selling basic data collection platforms without clinical decision support.
"Nobody waits for the next appointment to find out a patient is declining anymore. The device already called it in three days ago."
Senior Analyst, Connected Health and Remote Monitoring Practice · MMA Medical Devices Practice · September 2026

Market Trends

AI-Powered Deterioration Prediction Replaces Manual Trend Review

Machine learning models can now continuously analyze vital sign patterns to predict patient deterioration days before symptoms become clinically apparent, replacing manual trend review that once required care coordinators to individually scan dashboards for concerning patterns across dozens of enrolled patients simultaneously. This predictive capability is the single biggest reason remote monitoring platform adoption accelerated so sharply over the past several years compared with the previous decade of comparatively passive data collection approaches. Vendors report meaningfully faster clinical intervention with AI-powered prediction versus manual dashboard review processes previously used. overall.
Market Impact: Chronic disease enrollment grew 40%

Value-Based Reimbursement Models Formalize Monitoring Coverage

Expanding value-based care reimbursement frameworks increasingly reward health systems for documented remote monitoring outcomes rather than reimbursing only in-clinic visits, a payment shift that periodic fee-for-service billing arrangements common a decade ago could not adequately support for continuous monitoring programs. This reimbursement formalization is pushing health systems toward platforms offering built-in outcome reporting templates rather than custom-built internal tracking systems that require ongoing maintenance as payer requirements evolve. Vendors report meaningfully faster reimbursement approval for enterprises using standardized outcome reporting platforms across most payer relationships. across most payer relationships currently in place overall.
Market Impact: Device costs fell roughly 35%

Market Opportunities and Growth Drivers

Aging Populations Require Continuous Chronic Disease Tracking

Expanding aging populations across major economies increasingly require continuous chronic disease tracking that periodic in-clinic visits cannot economically provide given the growing ratio of chronic disease patients to available primary care physician capacity across most developed healthcare systems. Health system administrators facing this capacity constraint increasingly treat remote monitoring as essential care delivery infrastructure rather than a discretionary technology purchase layered on top of adequate existing in-clinic visit scheduling capacity. Several large health systems report meaningfully expanded monitoring program enrollment following recent capacity constraint recognition programs. across most tracked health systems overall.
Market Impact: Policy uncertainty delays expansion 6 months

Falling Device Costs Expand Smaller Health System Access

Connected monitoring device component costs have fallen considerably as manufacturing volume scaled during the pandemic-era emergency deployment period, making comprehensive monitoring programs commercially viable for smaller regional health systems that previously could not justify the technology cost for their more limited enrolled patient populations. Smaller health systems that once relied entirely on periodic in-clinic visits are increasingly adopting connected monitoring programs, since the total cost of ownership calculation now favors continuous monitoring even for modest enrollment volume. Several smaller health systems report meaningfully expanded program adoption following recent cost declines.
Market Impact: Device adherence rates run 65% typically

Market Restraints and Challenges

Reimbursement Policy Uncertainty Limits Long-Term Investment

Health systems facing uncertainty about whether current remote monitoring reimbursement codes will remain stable over the multi-year investment horizon required to justify comprehensive platform deployment sometimes delay expanding programs beyond initial pilot enrollment, since policy reversal could strand capital investment in monitoring infrastructure. The root cause traces to payer policy that remains subject to periodic legislative and regulatory review, creating genuine uncertainty about long-term reimbursement stability that health system finance officers must factor into investment decisions. Health systems are increasingly negotiating multi-year value-based contracts directly with payers to reduce this policy uncertainty for program investment planning.
Market Impact: Early intervention rates rose roughly 45%

Patient Engagement Challenges Limit Program Effectiveness

Many enrolled patients struggle to maintain consistent device usage over extended monitoring periods, particularly among elderly populations less comfortable with connected technology, undermining the continuous data collection that monitoring programs depend upon for accurate deterioration prediction and clinical decision support. The underlying cause is inadequate patient onboarding and ongoing engagement support that many programs underinvest in relative to the technology deployment itself, leaving patients without sufficient support to maintain long-term device usage habits. Vendors are increasingly offering dedicated patient engagement support services to reduce this adherence gap for enrolled patient populations.
Market Impact: Value-based contracts covered 38% of programs
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

The Connected RHM Market splits into six product-defined segments spanning condition type and monitoring modality. AI-powered chronic disease monitoring platforms lead growth as value-based care expands, followed closely by cardiac remote monitoring devices, since both categories directly address the continuous tracking pressures driving procurement nationwide. Respiratory and vital sign monitoring round out the segment mix.
connected-rhm-remote-healthcare-monitoring-market-market-share-analysis-1788423534128

AI-Powered Chronic Disease Monitoring Platforms

AI-powered chronic disease monitoring platforms lead all segments because they concentrate the exact use case driving current health system procurement: continuous data analysis across diabetic, cardiac, and hypertensive patient populations that manual review processes cannot realistically scale to support given the growing enrollment volume modern value-based care contracts require. Health systems favor this segment since it directly addresses the predictive intervention capability that increasingly shapes value-based contract performance, capturing measurable hospitalization reduction within a single enrollment year. Large health systems managing complex multi-condition patient populations are increasingly standardizing on this segment across their entire care management portfolio. MMA estimates this segment alone will represent well over a third of total category revenue by 2036.
CAGR 17.0%

Cardiac Remote Monitoring Devices

Cardiac remote monitoring devices rank second in growth as health systems increasingly require continuous rhythm and vital sign tracking for heart failure and arrhythmia patients that periodic in-clinic visits cannot adequately capture given how quickly cardiac events can develop between scheduled appointments. These devices let care teams intervene during the earliest stages of decompensation, closely matching the clinical vigilance that cardiology guidelines increasingly recommend for high-risk patient populations. Health systems increasingly cite cardiac monitoring data directly within value-based contract performance reporting rather than treating it as a standalone technology purchase. MMA expects this category to scale steadily as cardiology guidelines continue formalizing continuous monitoring recommendations across most patient risk tiers.
CAGR 13.5%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America leads the Connected RHM Market given its established reimbursement infrastructure and highest overall health system remote monitoring spending nationwide, while East Asia follows closely through expanding aging population health programs driving mandatory monitoring adoption across most major metropolitan cities and remote rural regions.

North America

United States health systems drive the bulk of regional demand, reflecting substantial remote monitoring reimbursement infrastructure and established medical device manufacturer headquarters concentrated across major healthcare technology hubs nationwide. Canadian health systems are following a similar pattern, particularly among provinces expanding chronic disease management programs requiring continuous monitoring capacity. Philips and Medtronic, both headquartered in the region, maintain deep health system relationships that accelerate connected monitoring adoption across large integrated delivery networks and community health systems alike. Health system procurement cycles in the region also tend to move faster than in more fragmented regulatory environments, letting vendors close large multi-year contracts within a single fiscal budget cycle rather than waiting years for staged rollout approval across facilities.
Share: 32% | CAGR: 11.5% (2026 to 2036)

Western Europe

Germany and the United Kingdom lead regional adoption, integrating connected monitoring into expanding national health service chronic disease management programs already well underway across each country's public healthcare infrastructure. France and the Netherlands follow through strong domestic digital health investment supporting aging population care programs. Regional data protection rules add meaningful compliance overhead for vendors processing extensive patient health data across multiple national jurisdictions simultaneously. Regional vendors increasingly bundle monitoring devices with broader chronic disease management consulting services, letting health systems address device deployment, compliance, and outcome documentation planning within a single coordinated vendor engagement rather than separate procurement tracks. Vendors report this bundling meaningfully improves subscription retention across the region's largest public healthcare markets specifically today.
Share: 19% | CAGR: 11.0% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
connected-rhm-remote-healthcare-monitoring-market-country-cagr-analysis-1788423534659

How Vendors Capture Chronic Care Value

Vendors capture value across four distinct commercial mechanisms as connected monitoring moves from pilot programs toward permanent chronic care infrastructure, extending revenue well beyond a base device sale into recurring analytics, reporting, engagement, and fleet relationships that compound steadily over each health system's multi-year value-based contract and renewal cycle. Vendors executing all four pull ahead of single-mechanism rivals.

Tiered Per-Patient Monthly Subscription Pricing Model

Vendors price core monitoring subscriptions on a per-enrolled-patient monthly basis, with premium tiers opening additional condition modules such as predictive analytics or multi-condition tracking that command substantially higher pricing than basic single-condition monitoring alone. This pricing model anchors baseline recurring revenue, since health systems rarely downgrade modules once care teams depend on consolidated dashboards spanning multiple chronic conditions simultaneously. Large health system accounts typically carry premium module pricing roughly 30% above base subscription rates given the added clinical coverage value delivered. Vendors report this module structure still protects overall margin given lower per-module support costs at scale.
Market Impact: Premium module subscribers pay roughly 30% more overall

Outcome Reporting and Value-Based Documentation Services

Vendors increasingly sell dedicated outcome reporting services that aggregate monitoring results into value-based contract documentation formats, saving health system quality teams considerable manual reporting effort during payer performance reviews. This packaged reporting capability commands a meaningful price premium over raw monitoring data alone, since health systems value the time savings and reduced audit risk more than the underlying data itself. Some vendors now generate roughly 22% of total account revenue from these outcome reporting subscriptions. Health systems increasingly bundle this reporting service into initial contract negotiations rather than purchasing separately later.
Market Impact: Outcome reporting adds roughly 22% of total revenue

Patient Engagement and Adherence Support Contracts

Vendors sell dedicated patient engagement consulting that helps health systems maintain consistent device usage among enrolled patients, since navigating patient adherence barriers requires specialized behavioral health expertise most health systems lack internally. This consulting revenue carries exceptionally high margins compared with the underlying device subscription, drawing on specialized engagement expertise vendors have developed across many enrollment programs. Some vendors now generate roughly 16% of total account revenue from these engagement support services. Health systems often renew these engagement contracts annually as new enrollment cohorts require onboarding support. across most large health system accounts overall.
Market Impact: Engagement services add roughly 16% of total revenue

Device Replacement and Fleet Management Contracts

Vendors sell dedicated fleet management contracts that handle device replacement, sanitization, and redeployment across an enrolled patient population, reducing the logistics burden that health systems consider costly given how central continuous device availability has become to program effectiveness. This bundled offering carries substantially higher margins than standard device sales alone, since fleet management service costs little to deliver at scale once regional logistics infrastructure is built. Health systems adopting this bundle report contract values running roughly 2 times higher over the program's full operating lifespan. across most program deployments overall.
Market Impact: Fleet contracts lift lifetime value 2 times over

Who Controls the Margin Pool

Five vendors, evaluated on annual recurring revenue from connected monitoring devices and platforms, together account for an estimated 36% of tracked market revenue, leaving a long tail of specialists competing for remaining health system budget. Philips leads through existing hospital equipment relationships and platform breadth, while Medtronic and Teladoc Health compete closely for health system contracts that neither incumbent fully dominates across every condition segment.
Current competitive activity centers on predictive analytics expansion, as every major vendor races to add machine learning deterioration prediction capability rather than competing purely on basic vital sign collection functionality alone. Partnership announcements between monitoring platform vendors and value-based care organizations have become a common deal structure over the past two years, extending outcome documentation credibility without requiring vendors to build comparable clinical relationships entirely from scratch internally.

Emerging pressure comes from consumer wearable manufacturers who could add clinical-grade monitoring certification to their existing fitness device platforms, potentially disintermediating standalone medical monitoring vendors for cost-conscious health systems. Rankings could shift meaningfully if a major technology platform acquires a leading remote monitoring specialist outright, combining device scale with existing consumer relationships that smaller specialists currently cannot match alone.
connected-rhm-remote-healthcare-monitoring-market-company-positioning-matrix-1788423535186

Competitive Moat and Risk Dimensions

PHILIPS

Moat: Broad Hospital Equipment Relationship Reach

Philips' broad hospital equipment portfolio gives it cross-selling reach into existing health system customer relationships that narrower monitoring-only specialists cannot replicate easily, letting the company bundle remote monitoring with existing imaging and patient monitoring equipment sales. This portfolio breadth wins health system contracts that pure-play monitoring vendors cannot easily secure alone.
PHILIPS

Risk: Complex Portfolio Slows Monitoring Focus

Philips' broad portfolio spanning many healthcare technology categories can dilute research and development focus compared with specialized remote monitoring competitors dedicating their entire engineering effort to advancing predictive analytics and patient engagement capability specifically. This focus gap could limit its ability to match specialist innovation pace in narrower monitoring categories.
TELADOC HEALTH

Moat: Established Virtual Care Platform Scale

Teladoc Health's existing virtual care platform and large enrolled patient base give it distribution scale for remote monitoring services that newer monitoring-only entrants cannot replicate quickly, letting the company cross-sell monitoring into an already vast telehealth customer relationship. This scale advantage compounds as the platform continues expanding into new condition categories.
TELADOC HEALTH

Risk: Limited Proprietary Hardware Capability

Teladoc Health depends largely on third-party device partners for the physical monitoring hardware its platform operates, leaving the company exposed to device pricing and supply decisions made by manufacturers pursuing their own competing platform strategies. A major hardware partner favoring a rival platform could disrupt this dependency meaningfully.

Players Tracked

Prominent Players

Philips
Medtronic
Teladoc Health
Vivify Health
Biotricity

Other Key Players

Abbott Laboratories
Dexcom
iRhythm Technologies
Masimo
GE HealthCare
Withings
Vivalink
Current Health (Best Buy Health)
AMC Health
CareSimple
Cadence Health
Optimize Health
Cardiovascular Systems
BioIntelliSense
Health Recovery Solutions

Recent Developments

FEBRUARY 2025

Philips launched an enhanced chronic disease monitoring platform incorporating machine learning deterioration prediction directly into its existing hospital equipment platform, letting health systems activate predictive analytics without procuring a separate specialized software product. The rollout extended to conditional alerts covering third-party care management systems connected through the platform's data pipeline.
Signal: Signals platform incumbents are now increasingly bundling advanced analytics directly into infrastructure health systems trust deeply.
JULY 2025

Teladoc Health announced a strategic partnership with a major device manufacturer to expand its remote monitoring hardware options, adding new condition-specific devices to its existing virtual care platform coverage. The partnership initially covers select major health system accounts with plans for broader hardware availability expansion.
Signal: Signals virtual care platforms are now increasingly pursuing hardware partnerships to deepen condition-specific monitoring capability overall.
OCTOBER 2025

Medtronic acquired a smaller patient engagement analytics startup specializing in adherence prediction algorithms, adding behavioral analytics capability to its existing remote monitoring product portfolio ahead of planned integration. The acquired team will be integrated into Medtronic's existing product engineering and digital health innovation division overall.
Signal: Signals established medical device vendors are now increasingly acquiring engagement capability rather than building internally now.

Cloud Infrastructure and Sensor Cost Exposure

Cloud computing infrastructure account for an estimated 32% of total cost of delivering connected monitoring platforms, sourced primarily from major hyperscale cloud providers running the machine learning models underlying deterioration prediction. Specialized biosensor components represent a second meaningful cost input, concentrated among a limited pool of medical-grade sensor manufacturers. Component sourcing remains concentrated among a small number of qualified providers globally.
A notable cloud computing pricing increase from a major hyperscale provider in mid-2025, documented in that provider's own investor communications, pushed several smaller monitoring platform vendors to renegotiate hosting contracts or migrate workloads to alternative providers entirely. The transition period created temporary service reliability concerns for a handful of health system customers during the multi-week migration window. Delivery timelines gradually normalized within roughly two months as broader supply conditions eased across the industry considerably.

Smaller monitoring platform vendors lacking negotiating leverage with hyperscale cloud providers pay meaningfully higher per-unit compute costs than larger competitors who can commit to substantial multi-year volume agreements. This dynamic disproportionately affects newer entrants without established health system customer bases large enough to justify long-term infrastructure commitments comparable to incumbents. Vendors with existing scale weathered the recent pricing pressure better than newer entrants.
connected-rhm-remote-healthcare-monitoring-market-cost-volatility-analysis-1788423535380

Multi-Provider Cloud Sourcing Strategy

Leading vendors increasingly distribute workloads across two or more cloud providers to reduce dependency on any single hosting relationship and preserve negotiating leverage during contract renewal cycles. This redundancy adds modest complexity but meaningfully lowers concentration risk. Vendors report meaningfully improved cost predictability once multi-year agreements are secured well ahead of large deployments. overall.

In-House Sensor Component Development

Some vendors are building internal biosensor design capability rather than relying entirely on third-party component suppliers, reducing dependency on external manufacturers and improving long-term margin control. This approach requires upfront investment but improves cost predictability. Several vendors expect this approach to meaningfully reduce dependency on external suppliers during future component shortages. across most product lines overall.

Portfolio Architecture for Margin Defence

Vendors architect pricing around three distinct tiers separating basic single-condition monitoring from certified multi-condition platforms and next-generation AI-powered predictive systems still scaling from early deployment. Gross margins widen considerably as revenue moves up this tier structure, since higher tiers embed proprietary analytics and reporting support competitors cannot easily replicate. Vendors moving customers up this structure see improved profitability over successive contract renewal cycles.
Basic single-condition monitoring revenue carries margins comparable to conventional medical device manufacturing, while premium tiers bundling predictive analytics and outcome reporting command noticeably higher per-patient pricing. This tension between enrollment volume scale and premium analytics differentiation shapes most vendor product roadmap decisions currently under active development. Vendors design roadmaps to nudge volume-tier customers upward through bundled trial access to analytics features.

The highest-value pools concentrate among large health systems willing to pay for predictive platforms that integrate directly with value-based contract reporting and electronic health record systems rather than functioning as standalone monitoring hardware. Smaller vendors without this integration capability increasingly compete on price within the volume tier alone, ceding higher-margin premium health system accounts to larger established platform incumbents. Vendors investing early in this integration are positioned to capture outsized share of this pool.

Basic single-condition monitoring subscriptions priced comparably to standard medical device manufacturing, targeting cost-sensitive smaller health systems without complex outcome reporting or predictive analytics requirements attached. These accounts value predictable flat pricing over advanced feature depth entirely.
Gross Margin

Multi-condition platforms bundling predictive analytics and value-based reporting capability, targeting large health systems commanding meaningfully higher recurring margins given embedded documentation functionality. Renewal rates in this tier run notably higher than the volume segment overall.
Gross Margin

AI-powered predictive systems with expanded deterioration forecasting capability, still scaling from early deployment, priced at the highest premium given differentiated proprietary technology involved. Commercial availability remains limited to a handful of early pilots currently.
Gross Margin
connected-rhm-remote-healthcare-monitoring-market-portfolio-architecture-1788423535872

High-value Sub-segments and Strategic Watch-out

AI-Powered Chronic Disease Monitoring Platforms

This segment combines the fastest growth rate in the market with the strongest margin profile, as value-based care expands while health systems pay premium pricing for predictive capability that materially reduces hospitalization risk. MMA rates this segment the strongest combined opportunity in the entire portfolio.

Cardiac Remote Monitoring Devices

Strong growth continues here as cardiology guidelines formalize, though margins run somewhat thinner than chronic disease platforms given intensifying competition among vendors offering broadly comparable monitoring capability. Vendors should still prioritize investment here given the large addressable health system base. Early results show strong customer satisfaction.

Diabetes and Glucose Monitoring Systems

This established segment anchors reliable core revenue for vendors serving most enrolled patients, growing more slowly than platform-specific alternatives but maintaining loyal customers with long-standing procurement relationships. This segment remains a dependable core revenue source for established vendors. Loyal customers renew consistently. across most tracked customer accounts overall.

Respiratory Monitoring Devices

Growth here trails the broader market meaningfully, and vendors should watch closely for signs of accelerating displacement by more integrated multi-condition monitoring categories that offer comparable coverage without requiring separate devices. Vendors should monitor renewal rates closely for early signs of accelerating decline. across most tracked accounts overall.

The Value-Based Annuity Behind Chronic Monitoring

Remote monitoring platform contracts function much like a value-based annuity, since renewal happens automatically each budget cycle once a health system's care management and quality teams depend on consolidated outcome reporting for payer contract performance. This gives vendors predictable revenue visibility once a health system completes initial enrollment. Churn for fully enrolled health systems runs notably lower than typical medical technology, since switching cost grows each renewal year.
Adoption depth varies meaningfully by end-use vertical: cardiac and diabetes management programs embed connected monitoring deeply given clear measurable hospitalization reduction benefits, while smaller specialty practices often see lighter deployment, leaving routine chronic care on periodic visits considerably longer. Respiratory and post-surgical recovery programs occupy a middle ground, adopting monitoring selectively for higher-risk patients.

Buyer profiles are shifting generationally as care coordinators who built careers on manual chart review give way to a newer cohort trained on continuous dashboard-driven care management from early in their careers. This shift accelerates procurement, since newer buyers arrive already comfortable evaluating platform-generated risk scores. Vendors report shorter sales cycles engaging this cohort, since advocacy increasingly comes from within care teams rather than executives.
connected-rhm-remote-healthcare-monitoring-market-end-use-penetration-index-1788423536355

Where Vendors Should Focus Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / OUTCOME-LED SALES MOTION

Lead health system sales with hospitalization data, not features

Documented hospitalization reduction data closes health system deals faster than any feature comparison exercise, since value-based contracting committees now approve platform budget directly based on measurable outcome results rather than deferring entirely to individual physicians. Vendors that lead sales conversations with specific outcome data convert prospects meaningfully faster than those leading purely with device specifications or feature claims alone. This approach matters most for vendors selling into health systems managing large chronic disease populations facing the steepest value-based contract performance pressure.
02 / PREDICTIVE ANALYTICS INVESTMENT

Build predictive deterioration models ahead of rivals

Predictive analytics capability increasingly determines which monitoring vendor captures the highest-value health system contracts, since care teams now compare deterioration prediction accuracy across competing platforms rather than a single flat monitoring price point. Vendors offering more accurate predictive models convert casual monitoring buyers into premium platform buyers meaningfully faster than those offering only basic data collection without predictive capability. This approach matters most for vendors competing directly against rivals with more established clinical analytics infrastructure and considerably deeper analytics expertise overall.
03 / PATIENT ENGAGEMENT INVESTMENT

Expand patient engagement support ahead of adherence challenges

Patient adherence challenges remain the single largest bottleneck limiting broader monitoring program effectiveness across most health systems tracked in this study, regardless of how sophisticated the underlying monitoring technology genuinely is. Vendors offering credible patient engagement support that reduces this adherence burden can shorten health system sales cycles meaningfully compared with rivals selling devices alone without accompanying engagement expertise. This investment pays off most clearly among health systems serving elderly and lower-technology-literacy patient populations facing quite steep adherence risk currently.
04 / REGULATORY POLICY POSITIONING

Build reimbursement advocacy ahead of policy uncertainty

Reimbursement policy uncertainty remains a genuine risk for vendors dependent primarily on current remote monitoring payment codes that could shift with future legislative and regulatory review cycles affecting program funding. Vendors building credible policy advocacy relationships and diversified value-based contracting arrangements can reduce this dependency risk meaningfully compared with vendors relying entirely on a single reimbursement mechanism for revenue. This approach matters most for vendors currently dependent primarily on fee-for-service reimbursement models without any diversified contracting arrangements currently established at all.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Connected RHM (Remote Healthcare Monitoring) Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Connected RHM (Remote Healthcare Monitoring) Exposure Evaluation 2025-26
CLIENT PROFILE
A regional health system managing a large population of diabetic and cardiac patients under a new value-based contract faced pressure to reduce hospitalization rates that its existing periodic in-clinic visit model could not adequately address given the growing patient volume relative to available physician appointment capacity. Leadership needed connected monitoring across its highest-risk patients without expanding clinical staff significantly, facing pressure to show measurable outcome improvement ahead of the review.
STRATEGIC CHALLENGE
Leadership needed to determine whether connected remote monitoring could meaningfully reduce hospitalization rates without requiring a large dedicated care management team, and faced pressure to show measurable results within a single fiscal year to satisfy the value-based contract performance review affecting future payer reimbursement rates significantly. Board members also wanted assurance the transition would not overwhelm existing care coordinator capacity.
MMA APPROACH
MMA benchmarked three candidate monitoring platforms against the health system's specific patient population, existing electronic health record compatibility, and care team capacity, then modeled expected hospitalization reduction and full multi-year total cost of ownership across each platform option under consideration for this particular contract. Findings were shared with the health system's care management leadership ahead of final platform selection.
KEY FINDINGS
  1. Connected monitoring reduced hospitalization rates meaningfully among enrolled patients within the first year (client-reported, unverified by MMA) across the population. across the enrolled population overall.
  2. Care coordinators reported improved ability to prioritize outreach once platform-generated risk scores identified deteriorating patients earlier. This capability meaningfully improved overall care team efficiency and outreach prioritization.
  3. The value-based contract performance review acknowledged the documented outcome improvement during the subsequent annual evaluation process. This recognition strengthened the health system's case for continued program investment overall.
  4. Patient satisfaction scores improved once enrolled patients reported feeling more closely monitored between scheduled clinic visits. This improvement meaningfully strengthened the health system's overall patient retention outcomes.
CLIENT PROFILE
A regional health system managing a large population of diabetic and cardiac patients under a new value-based contract faced pressure to reduce hospitalization rates that its existing periodic in-clinic visit model could not adequately address given the growing patient volume relative to available physician appointment capacity. Leadership needed connected monitoring across its highest-risk patients without expanding clinical staff significantly, facing pressure to show measurable outcome improvement ahead of the review.
STRATEGIC CHALLENGE
Leadership needed to determine whether connected remote monitoring could meaningfully reduce hospitalization rates without requiring a large dedicated care management team, and faced pressure to show measurable results within a single fiscal year to satisfy the value-based contract performance review affecting future payer reimbursement rates significantly. Board members also wanted assurance the transition would not overwhelm existing care coordinator capacity.
MMA APPROACH
MMA benchmarked three candidate monitoring platforms against the health system's specific patient population, existing electronic health record compatibility, and care team capacity, then modeled expected hospitalization reduction and full multi-year total cost of ownership across each platform option under consideration for this particular contract. Findings were shared with the health system's care management leadership ahead of final platform selection.
KEY FINDINGS
  1. Connected monitoring reduced hospitalization rates meaningfully among enrolled patients within the first year (client-reported, unverified by MMA) across the population. across the enrolled population overall.
  2. Care coordinators reported improved ability to prioritize outreach once platform-generated risk scores identified deteriorating patients earlier. This capability meaningfully improved overall care team efficiency and outreach prioritization.
  3. The value-based contract performance review acknowledged the documented outcome improvement during the subsequent annual evaluation process. This recognition strengthened the health system's case for continued program investment overall.
  4. Patient satisfaction scores improved once enrolled patients reported feeling more closely monitored between scheduled clinic visits. This improvement meaningfully strengthened the health system's overall patient retention outcomes.
RECOMMENDED STRATEGY
Phase 1: Phase one selected a platform meeting both patient population needs and existing electronic health record compatibility precisely. and budget constraints. Phase 2: Phase two enrolled the highest-risk patient cohort first before expanding to the broader eligible patient population. to validate results first. Phase 3: Phase three trained care coordinators on interpreting platform-generated risk scores within existing daily workflow routines. and new reporting workflows used.
OUTCOME
The health system reduced hospitalization rates among enrolled patients and secured favorable terms during its subsequent value-based contract performance review (client-reported, unverified by MMA), while improving patient satisfaction scores across its enrolled chronic disease population. Health system leadership credited the phased rollout with meaningfully strengthening overall care team confidence and workflow adoption.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Connected RHM Market?

The Connected RHM Market reached an estimated $9.5 billion in global revenue in 2025. This covers connected devices and software platforms for continuous remote monitoring of chronic disease patients worldwide.

How large will the Connected RHM Market be by 2036?

MMA projects the market will reach approximately $33.05 billion by 2036, driven mainly by value-based care reimbursement and aging population health programs. That represents roughly a 3.11 fold expansion from 2026 levels.

What is the CAGR for the Connected RHM Market 2026 to 2036?

The market is forecast to grow at a 12.0% compound annual rate between 2026 and 2036. Bull and bear scenarios range between roughly 10.7% and 13.3% depending on reimbursement policy stability.

Which segment is growing fastest?

AI-powered chronic disease monitoring platforms lead all segments, expanding at an estimated 17.0% annually. That is well above the overall market's 12.0% average growth rate through the forecast period to 2036.

Who are the major companies in the Connected RHM Market?

Philips, Medtronic, Teladoc Health, Vivify Health, and Biotricity form the five leading vendors tracked in this report. Together they hold an estimated 36% combined share of tracked platform revenue.

Which country is growing fastest?

India posts the fastest national growth rate in the study, expanding at an estimated 15.0% annually. Its expanding chronic disease burden and digital health infrastructure investment drive unusually rapid adoption there.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Primary Market Dimension

  • AI-Powered Chronic Disease Monitoring Platforms
  • Cardiac Remote Monitoring Devices
  • Diabetes and Glucose Monitoring Systems
  • Post-Acute and Surgical Recovery Monitoring
  • Respiratory Monitoring Devices
  • Vital Sign Monitoring Hubs and Software

By End-Use Industry

  • Hospitals and Integrated Delivery Networks
  • Community Health Systems
  • Home Health Agencies
  • Specialty Cardiology and Endocrinology Practices
  • Payers and Value-Based Care Organizations

By Commercial Dimension

  • Direct Health System Subscriptions
  • Payer-Sponsored Program Contracts
  • Distributor and Reseller Channel Sales
  • Patient Engagement Consulting Contracts

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, September 2026)
Market Definition
The Connected RHM Market covers connected devices and software platforms for continuous remote monitoring of patient vital signs and chronic disease indicators outside clinical settings, measured by device and subscription revenue. It excludes standalone consumer fitness wearables without clinical monitoring certification and general telehealth video consultation platforms.
Quantitative Units
USD Billion, CAGR (%), Share (%), 2020 to 2036
Segmentation Dimensions
By Primary Market Dimension; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
United States, Canada, United Kingdom, Germany, France, Netherlands, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, United Arab Emirates, South Africa, Poland
Key Companies Profiled
Philips, Medtronic, Teladoc Health, Vivify Health, Biotricity, Abbott Laboratories, Dexcom, iRhythm Technologies, Masimo, GE HealthCare, Withings, Vivalink, Current Health (Best Buy Health), AMC Health, CareSimple, Cadence Health, Optimize Health, Cardiovascular Systems, BioIntelliSense, Health Recovery Solutions
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-630
Published
September 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Connected RHM (Remote Healthcare Monitoring) Market Report (2026 to 2036).

The full report delivers a comprehensive analysis of the Connected RHM Market, covering historical performance from 2020 through 2025 and forecasts extending to 2036. It provides detailed segmentation across six primary product categories, seven regional markets, and competitive profiles of the twenty leading vendors shaping industry structure. Readers gain access to quantified demand drivers, restraints, and revenue lever analysis grounded in primary survey data and expert interviews. The report also includes a detailed input cost exposure assessment and portfolio tier framework for strategic planning purposes.
Seven-region market sizing and forecast data
Twenty vendor competitive profiles and positioning
Segment-level CAGR and revenue projections through 2036
Primary survey data from 3,800 respondents
Expert interview insights from 47 industry specialists
Revenue lever and portfolio tier strategic frameworks

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts